BACKGROUND: Hormonal contraception (HC) use by HIV-infected women has been identified by the World Health Organization as an important strategy for reducing vertical HIV transmission. Little is known about the factors associated with HC discontinuation among HIV-infected women. METHODS: We analyzed data from a prospective study of HC use among 231 HIV-infected users with oral contraceptive (OC) or injectable depot medroxyprogesterone acetate (DMPA) in Uganda and Zimbabwe. We used Kaplan-Meier survival curves to estimate the median duration of OC and DMPA use and use of any highly effective contraceptive method. Cox proportional hazards models were used to investigate factors associated with HC discontinuation. RESULTS: Median duration was 36 months [95% confidence interval (CI): 14 to 61] for OC use and 19 months (95% CI: 14 to 24) for DMPA use. Median duration of any highly effective method was 36 months (95% CI: 26 to N/A) for OC users and 22 months (95% CI: 14 to 38) for DMPA users. In multivariable analyses, living in Zimbabwe [hazard ratio (HR): 0.39; 95% CI: 0.18 to 0.83], no partner (HR: 7.18; 95% CI: 3.05 to 16.88), and cervical infection (HR: 1.99; 95% CI: 0.90 to 4.41) were associated with OC discontinuation. No partner (HR: 2.00; 95% CI: 1.12 to 3.58), nausea (HR: 1.84; 95% CI: 1.02 to 3.34), and excessive night sweats (HR: 1.80; 95% CI: 0.95 to 3.40) were associated with DMPA discontinuation. CONCLUSION: Long-term use of HC methods is acceptable to HIV-infected women. Women discontinue for a variety of reasons, primarily unrelated to HIV. Alternative methods and ongoing contraceptive counseling is essential to reduce unplanned pregnancies and vertical HIV transmission.
BACKGROUND: Hormonal contraception (HC) use by HIV-infectedwomen has been identified by the World Health Organization as an important strategy for reducing vertical HIV transmission. Little is known about the factors associated with HC discontinuation among HIV-infectedwomen. METHODS: We analyzed data from a prospective study of HC use among 231 HIV-infected users with oral contraceptive (OC) or injectable depot medroxyprogesterone acetate (DMPA) in Uganda and Zimbabwe. We used Kaplan-Meier survival curves to estimate the median duration of OC and DMPA use and use of any highly effective contraceptive method. Cox proportional hazards models were used to investigate factors associated with HC discontinuation. RESULTS: Median duration was 36 months [95% confidence interval (CI): 14 to 61] for OC use and 19 months (95% CI: 14 to 24) for DMPA use. Median duration of any highly effective method was 36 months (95% CI: 26 to N/A) for OC users and 22 months (95% CI: 14 to 38) for DMPA users. In multivariable analyses, living in Zimbabwe [hazard ratio (HR): 0.39; 95% CI: 0.18 to 0.83], no partner (HR: 7.18; 95% CI: 3.05 to 16.88), and cervical infection (HR: 1.99; 95% CI: 0.90 to 4.41) were associated with OC discontinuation. No partner (HR: 2.00; 95% CI: 1.12 to 3.58), nausea (HR: 1.84; 95% CI: 1.02 to 3.34), and excessive night sweats (HR: 1.80; 95% CI: 0.95 to 3.40) were associated with DMPA discontinuation. CONCLUSION: Long-term use of HC methods is acceptable to HIV-infectedwomen. Women discontinue for a variety of reasons, primarily unrelated to HIV. Alternative methods and ongoing contraceptive counseling is essential to reduce unplanned pregnancies and vertical HIV transmission.
Authors: Charles S Morrison; Barbra A Richardson; Francis Mmiro; Tsungai Chipato; David D Celentano; Joanne Luoto; Roy Mugerwa; Nancy Padian; Sungwal Rugpao; Joelle M Brown; Peter Cornelisse; Robert A Salata Journal: AIDS Date: 2007-01-02 Impact factor: 4.177
Authors: Elizabeth M Stringer; Jens Levy; Moses Sinkala; Benjamin H Chi; Inutu Matongo; Namwinga Chintu; Jeffrey S A Stringer Journal: AIDS Date: 2009-07-17 Impact factor: 4.177
Authors: Kimberly S H Yarnall; Colleen M McBride; Pauline Lyna; Laura J Fish; Diane Civic; Louis Grothaus; Delia Scholes Journal: Prev Med Date: 2003-08 Impact factor: 4.018
Authors: Karen E Mark; Jareen Meinzen-Derr; Rob Stephenson; Alan Haworth; Yusuf Ahmed; Dana Duncan; Andrew Westfall; Susan Allen Journal: J Womens Health (Larchmt) Date: 2007-10 Impact factor: 2.681
Authors: Catherine S Todd; Tracy C Anderman; Sarah Long; Landon Myer; Linda-Gail Bekker; Gregory A Petro; Heidi E Jones Journal: Contraception Date: 2018-02-09 Impact factor: 3.375
Authors: Daniel Westreich; Naiomi Jamal; Jennifer S Smith; Doreen Schulze; Sophie Williams; Pam Michelow; Simon Levin; Cynthia Firnhaber Journal: Contraception Date: 2014-01-07 Impact factor: 3.375